相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
Philip Cornford et al.
EUROPEAN UROLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Nicolas Mottet et al.
EUROPEAN UROLOGY (2021)
Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer
Shidong Lv et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer
Wout Devlies et al.
CANCERS (2021)
Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on
Eva Estebanez-Perpina et al.
CANCERS (2021)
Enzalutamide-induced Proteolytic Degradation of the Androgen Receptor in Prostate Cancer Cells Is Mediated Only to a Limited Extent by the Proteasome System
Holger H. H. Erb et al.
ANTICANCER RESEARCH (2021)
Androgen receptor degraders over come common resistance mechanisms developed during prostate cancer treatment
Steven Kregel et al.
NEOPLASIA (2020)
Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer
Holger H. H. Erb et al.
PLOS ONE (2020)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
Kenrick Ng et al.
ONCOLOGY AND THERAPY (2020)
Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms
Shiv Verma et al.
CANCER DRUG RESISTANCE (2020)
Interference with the androgen receptor protein stability in therapy-resistant prostate cancer
Gopinath Lakshmana et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
The androgen receptor antagonist enzalutamide induces apoptosis, dysregulates the heat shock protein system, and diminishes the androgen receptor and estrogen receptor β1 expression in prostate cancer cells
Alexander Abazid et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D. Davis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Kim N. Chi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Role of Androgen Receptor in Prostate Cancer: A Review
Kazutoshi Fujita et al.
WORLD JOURNAL OF MENS HEALTH (2019)
A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer
Daniel Hyuck-Min Kwon et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models
Florian Handle et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer
Chengfei Liu et al.
NATURE COMMUNICATIONS (2018)
The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy
Martin Puhr et al.
CLINICAL CANCER RESEARCH (2018)
Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial
Axel Heidenreich et al.
EUROPEAN UROLOGY (2017)
Androgen receptor splice variants and prostate cancer: From bench to bedside
Kristine M. Wadosky et al.
Oncotarget (2017)
Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance
Daniel J. Crona et al.
CANCERS (2017)
PC-1 works in conjunction with E3 ligase CHIP to regulate androgen receptor stability and activity
Jian Wang et al.
ONCOTARGET (2016)
Primary versus castration-resistant prostate cancer: modeling through novel murine prostate cancer cell lines
Georges Daoud et al.
ONCOTARGET (2016)
Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
Julia Hoefer et al.
ONCOTARGET (2016)
Emerging mutations and functional changes of androgen receptor associated with treatment resistance in prostate cancer
Filippo Martignano et al.
TRANSLATIONAL CANCER RESEARCH (2016)
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients
Nada Lallous et al.
GENOME BIOLOGY (2016)
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
Karim Fizazi et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells
Nobuyuki Ishikura et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Antiandrogens Act as Selective Androgen Receptor Modulators at the Proteome Level in Prostate Cancer Cells
Greg N. Brooke et al.
MOLECULAR & CELLULAR PROTEOMICS (2015)
Therapy escape mechanisms in the malignant prostate
Frederic R. Santer et al.
SEMINARS IN CANCER BIOLOGY (2015)
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
Anu-Maarit Moilanen et al.
SCIENTIFIC REPORTS (2015)
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Nicola J. Clegg et al.
CANCER RESEARCH (2012)
Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
Rachel M. Squillace et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
The Impact of Point Mutations in the Human Androgen Receptor: Classification of Mutations on the Basis of Transcriptional Activity
Colin W. Hay et al.
PLOS ONE (2012)
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis
Charles E. Massie et al.
EMBO JOURNAL (2011)
PC3 Is a Cell Line Characteristic of Prostatic Small Cell Carcinoma
Sheng Tai et al.
PROSTATE (2011)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
分享论文
